135 related articles for article (PubMed ID: 26577926)
1. Peptidyl Arginine Deiminases and Neurodegenerative Diseases.
Tu R; Grover HM; Kotra LP
Curr Med Chem; 2016; 23(2):104-14. PubMed ID: 26577926
[TBL] [Abstract][Full Text] [Related]
2. Protein Arginine Deiminases (PADs): Biochemistry and Chemical Biology of Protein Citrullination.
Mondal S; Thompson PR
Acc Chem Res; 2019 Mar; 52(3):818-832. PubMed ID: 30844238
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of peptidyl-arginine deiminases reverses protein-hypercitrullination and disease in mouse models of multiple sclerosis.
Moscarello MA; Lei H; Mastronardi FG; Winer S; Tsui H; Li Z; Ackerley C; Zhang L; Raijmakers R; Wood DD
Dis Model Mech; 2013 Mar; 6(2):467-78. PubMed ID: 23118341
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of tetrazole analogs of Cl-amidine as protein arginine deiminase inhibitors.
Subramanian V; Knight JS; Parelkar S; Anguish L; Coonrod SA; Kaplan MJ; Thompson PR
J Med Chem; 2015 Feb; 58(3):1337-44. PubMed ID: 25559347
[TBL] [Abstract][Full Text] [Related]
5. Substrate specificity and kinetic studies of PADs 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3.
Knuckley B; Causey CP; Jones JE; Bhatia M; Dreyton CJ; Osborne TC; Takahara H; Thompson PR
Biochemistry; 2010 Jun; 49(23):4852-63. PubMed ID: 20469888
[TBL] [Abstract][Full Text] [Related]
6. The protein arginine deiminases: Structure, function, inhibition, and disease.
Bicker KL; Thompson PR
Biopolymers; 2013 Feb; 99(2):155-63. PubMed ID: 23175390
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of peptidyl-arginine deiminase (PAD): can it control multiple inflammatory disorders as a promising therapeutic strategy?
Padhy DS; Palit P; Ikbal AMA; Das N; Roy DK; Banerjee S
Inflammopharmacology; 2023 Apr; 31(2):731-744. PubMed ID: 36806957
[TBL] [Abstract][Full Text] [Related]
8. Identification of multiple structurally distinct, nonpeptidic small molecule inhibitors of protein arginine deiminase 3 using a substrate-based fragment method.
Jamali H; Khan HA; Stringer JR; Chowdhury S; Ellman JA
J Am Chem Soc; 2015 Mar; 137(10):3616-21. PubMed ID: 25742366
[TBL] [Abstract][Full Text] [Related]
9. Neuronal PAD4 expression and protein citrullination: possible role in production of autoantibodies associated with neurodegenerative disease.
Acharya NK; Nagele EP; Han M; Coretti NJ; DeMarshall C; Kosciuk MC; Boulos PA; Nagele RG
J Autoimmun; 2012 Jun; 38(4):369-80. PubMed ID: 22560840
[TBL] [Abstract][Full Text] [Related]
10. Peptidylarginine Deiminase and Alzheimer's Disease.
Wang L; Chen H; Tang J; Guo Z; Wang Y
J Alzheimers Dis; 2022; 85(2):473-484. PubMed ID: 34842193
[TBL] [Abstract][Full Text] [Related]
11. Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential.
Jones JE; Causey CP; Knuckley B; Slack-Noyes JL; Thompson PR
Curr Opin Drug Discov Devel; 2009 Sep; 12(5):616-27. PubMed ID: 19736621
[TBL] [Abstract][Full Text] [Related]
12. Noncovalent Protein Arginine Deiminase (PAD) Inhibitors Are Efficacious in Animal Models of Multiple Sclerosis.
Tejeda EJC; Bello AM; Wasilewski E; Koebel A; Dunn S; Kotra LP
J Med Chem; 2017 Nov; 60(21):8876-8887. PubMed ID: 29045782
[TBL] [Abstract][Full Text] [Related]
13. Methylation of arginine residues interferes with citrullination by peptidylarginine deiminases in vitro.
Raijmakers R; Zendman AJ; Egberts WV; Vossenaar ER; Raats J; Soede-Huijbregts C; Rutjes FP; van Veelen PA; Drijfhout JW; Pruijn GJ
J Mol Biol; 2007 Apr; 367(4):1118-29. PubMed ID: 17303166
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of protein arginine deiminases and their efficacy in animal models of multiple sclerosis.
Sarswat A; Wasilewski E; Chakka SK; Bello AM; Caprariello AV; Muthuramu CM; Stys PK; Dunn SE; Kotra LP
Bioorg Med Chem; 2017 May; 25(9):2643-2656. PubMed ID: 28341402
[TBL] [Abstract][Full Text] [Related]
15. A FluoPol-ABPP PAD2 high-throughput screen identifies the first calcium site inhibitor targeting the PADs.
Lewallen DM; Bicker KL; Madoux F; Chase P; Anguish L; Coonrod S; Hodder P; Thompson PR
ACS Chem Biol; 2014 Apr; 9(4):913-21. PubMed ID: 24467619
[TBL] [Abstract][Full Text] [Related]
16. Development of a highly sensitive fluorescence probe for peptidyl arginine deiminase (PAD) activity.
Kunieda K; Kawaguchi M; Ieda N; Nakagawa H
Bioorg Med Chem Lett; 2019 Apr; 29(7):923-928. PubMed ID: 30773431
[TBL] [Abstract][Full Text] [Related]
17. Peptidomimetics as protein arginine deiminase 4 (PAD4) inhibitors.
Trabocchi A; Pala N; Krimmelbein I; Menchi G; Guarna A; Sechi M; Dreker T; Scozzafava A; Supuran CT; Carta F
J Enzyme Inhib Med Chem; 2015 Jun; 30(3):466-71. PubMed ID: 25198885
[TBL] [Abstract][Full Text] [Related]
18. Novel small molecule protein arginine deiminase 4 (PAD4) inhibitors.
Bozdag M; Dreker T; Henry C; Tosco P; Vallaro M; Fruttero R; Scozzafava A; Carta F; Supuran CT
Bioorg Med Chem Lett; 2013 Feb; 23(3):715-9. PubMed ID: 23265898
[TBL] [Abstract][Full Text] [Related]
19. A fluopol-ABPP HTS assay to identify PAD inhibitors.
Knuckley B; Jones JE; Bachovchin DA; Slack J; Causey CP; Brown SJ; Rosen H; Cravatt BF; Thompson PR
Chem Commun (Camb); 2010 Oct; 46(38):7175-7. PubMed ID: 20740228
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization.
Luo Y; Arita K; Bhatia M; Knuckley B; Lee YH; Stallcup MR; Sato M; Thompson PR
Biochemistry; 2006 Oct; 45(39):11727-36. PubMed ID: 17002273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
